Trump and COVID-19: treatments to date

By Jenni Spinner

- Last updated on GMT

(Vacclav/iStock via Getty Images Plus)
(Vacclav/iStock via Getty Images Plus)

Related tags COVID-19 Coronavirus Regeneron Gilead Lilly Novartis

With the virus reaching the Oval Office, the presidential diagnosis is shining a spotlight on some of the drugs reportedly administered to the POTUS.

When news of US President Donald Trump’s positive COVID-19 test broke on the 24-hour news cycle in the wee hours of Friday morning, mainstream media scrambled for details about when he tested positive, severity of his case, and particulars of his treatment plan. Press conferences by doctors at Walter Reed National Military Medical Center (WRMC, the hospital Trump was whisked away to) and tweets from the Commander in Chief led to as much confusion as they did clarity, with initial announcements being later corrected by subsequent statements.

However, reports coming from the White House, Trump’s personal doctor, and WRMC spokespeople appear to converge on the president’s treatment strategy including three specific therapies:

  • Remdesivir, an antiviral
  • Dexamethasone, an anti-inflammatory
  • REGN-COV2, an antibody cocktail from Regeneron.

To date, there are no drugs approved by the US Food and Drug Administration (FDA) to treat and/or cure the virus, although Regeneron is one of the antibody cocktails in the running as a hopeful therapy (another being a similar product from Lilly​).

The following are the latest articles from Outsourcing-Pharma and BioPharma-Reporter on the drugs reportedly given to Trump in an attempt to get a handle on his COVID-19 case and varying symptoms.


Hovione to boost output of COVID-19 treatment excipient

FHI Clinical to support ACTT remdesivir trial for COVID-19

Gilead gets green light for inhaled remdesivir study

Gilead, Cipla partner on remdesivir expansion


Novartis launches NFP portfolio of COVID-19 treatments

AI Vivo: dexamethasone shows promise as COVID-19 treatment


Roche, Regeneron ally to triple supply of COVID-19 antibody cocktail

Regeneron targets September data drop from COVID-19 antibody trial

Regeneron COVID-19 antibody cocktail enters late-stage trials

Regeneron devotes New York facility to COVID-19 cocktail treatment

Our editors will continue to monitor the situation and offer updates as they become available.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

Related suppliers

Follow us


View more